At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 205 enrolled

Drug / intervention

Cabiralizumab +8 morebiological

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03336216

NCT03336216Phase 2Completed

Compare CT.gov

A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Bristol-Myers Squibb·interventional·Posted Nov 8, 2017·Updated Jul 23, 2024

In Brief

A Phase 2 clinical trial evaluating Cabiralizumab, Nab-paclitaxel, and 7 other interventions for Advanced Pancreatic Cancer. Completed, enrolled 205 participants across 41 sites in 11 countries.

Detailed Summary

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsAdvanced Pancreatic Cancer

CountriesCanada, Denmark, Germany, Italy, Japan, South Korea, Spain, Switzerland, Taiwan, United Kingdom, United States

Collaborators--

Timeline

Phase 2CompletedFinished

201820192020202120222023202420252026

First PostedNov 2017

Enrollment StartDec 2017

Primary CompletionJun 2023

TodayJul 2026

First PostedNov 8, 2017

Enrollment StartDec 18, 2017

Primary CompletionJun 1, 2023

TodayJul 2, 2026

Enrollment to primary: 5.5 yearsPosted 8.7 years ago